ATE439143T1 - Hm1.24 verwertende krebsvakzine - Google Patents

Hm1.24 verwertende krebsvakzine

Info

Publication number
ATE439143T1
ATE439143T1 AT03770047T AT03770047T ATE439143T1 AT E439143 T1 ATE439143 T1 AT E439143T1 AT 03770047 T AT03770047 T AT 03770047T AT 03770047 T AT03770047 T AT 03770047T AT E439143 T1 ATE439143 T1 AT E439143T1
Authority
AT
Austria
Prior art keywords
cancer vaccine
exploitable
protein
transduced
antigen
Prior art date
Application number
AT03770047T
Other languages
English (en)
Inventor
Yong Kwee
Masaaki Kosaka
Yasuo Koishihara
Original Assignee
Chugai Pharmaceutical Co Ltd
Univ London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Univ London filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE439143T1 publication Critical patent/ATE439143T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT03770047T 2002-10-30 2003-10-30 Hm1.24 verwertende krebsvakzine ATE439143T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002316639 2002-10-30
PCT/JP2003/013954 WO2004039398A1 (en) 2002-10-30 2003-10-30 Hm1.24-utilizing cancer vaccines

Publications (1)

Publication Number Publication Date
ATE439143T1 true ATE439143T1 (de) 2009-08-15

Family

ID=32211691

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03770047T ATE439143T1 (de) 2002-10-30 2003-10-30 Hm1.24 verwertende krebsvakzine

Country Status (7)

Country Link
US (1) US8652839B2 (de)
EP (1) EP1559432B1 (de)
JP (1) JP4716730B2 (de)
AT (1) ATE439143T1 (de)
AU (1) AU2003278603A1 (de)
DE (1) DE60328814D1 (de)
WO (1) WO2004039398A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080219974A1 (en) * 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
US8603481B2 (en) 2003-10-10 2013-12-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for solid tumors
JP2006141208A (ja) * 2004-11-16 2006-06-08 Univ Of Tokushima 多発性骨髄腫、白血病、悪性リンパ腫、肺癌等の免疫療法剤
US8329186B2 (en) 2004-12-20 2012-12-11 Isu Abxis Co., Ltd Treatment of inflammation using BST2 inhibitor
EP2064240A2 (de) * 2006-09-18 2009-06-03 Xencor, Inc. Optimierte auf hm1.24 abzielende antikörper
EP2281579A1 (de) 2009-08-05 2011-02-09 BioNTech AG Impfstoffzusammensetzung mit 5'-Cap-modifizierter RNA
CN107541513B (zh) * 2016-06-28 2020-11-17 深圳宾德生物技术有限公司 用于沉默cd317的小分子干扰rna、重组载体、药物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043703A1 (fr) * 1998-02-25 1999-09-02 Chugai Seiyaku Kabushiki Kaisha Technique de dosage immunochimique de l'anticorps anti-hm1.24
AU2001246846A1 (en) 2000-04-06 2001-10-23 Chugai Seiyaku Kabushiki Kaisha Immunoassay of anti-hm1.24 antibody
ES2254527T3 (es) * 2001-01-15 2006-06-16 I.D.M. Immuno-Designed Molecules Metodo para la preparacion de suspensiones de particulas submicronicas de agentes farmaceuticos.

Also Published As

Publication number Publication date
EP1559432B1 (de) 2009-08-12
US20060153883A1 (en) 2006-07-13
EP1559432A4 (de) 2006-05-17
JP2006508094A (ja) 2006-03-09
JP4716730B2 (ja) 2011-07-06
US8652839B2 (en) 2014-02-18
DE60328814D1 (de) 2009-09-24
EP1559432A1 (de) 2005-08-03
AU2003278603A1 (en) 2004-05-25
WO2004039398A1 (en) 2004-05-13
AU2003278603A8 (en) 2004-05-25

Similar Documents

Publication Publication Date Title
NO20020348D0 (no) Peptid acceptor ligeringsmetoder
CY1112735T1 (el) Πολυπεπτιδια δυναμενα εκμαιευσης μιας ανοσιακης αντιδρασης εναντι του καρκινου
DK1448595T3 (da) Antimikrobielle polypeptider
WO2004024757A3 (en) Modified pna molecules
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
EP1501863A4 (de) Kinaseankerproteinmuteine, peptide davon und damit im zusammenhang stehende verfahren
DK1265889T3 (da) Lægemidler imod virussygdomme
NO20043353L (no) Antistoff-inneholdende opplosningsfarmasoytika
CY1106431T1 (el) Γονοκοκκικες πρωτεϊνες και νουκλεϊκα οξεα
WO2005035003A3 (en) Compositions and methods for increasing drug efficiency
CY1105439T1 (el) Κυτταρα, μεθοδοι καλλιεργειας και η χρηση τους στη θepαπεια με αυτολογη μεταμοσχευση
CY1110793T1 (el) Εμβολιο φυματιωσης με βελτιωμενη αποτελεσματικοτητα
ATE469211T1 (de) Verbesserte sso7-polymerase-konjugat-proteine
DK1471926T3 (da) Sammensætninger og fremgangsmåder til terapeutisk anvendelse af en atonal-associeret sekvens
DE60322613D1 (de) Frostschutzproteine aus Basidiomyceten
ATE439143T1 (de) Hm1.24 verwertende krebsvakzine
DK1379695T3 (da) Nye polynukleotider og polypeptider af IFNalfa-21-genet
NO20073914L (no) Biologisk aktive peptider
CY1116649T1 (el) Τεχνητη dna αλληλουχια με βελτιστοποιημενη λειτουργια οδηγου σε 5' (5-utr) για βελτιωμενη εκφραση ετερολογων πρωτεϊνων σε φυτα
ATE497506T1 (de) Sars-verwandte proteine
WO2005013904A3 (en) Sars nucleic acids, proteins, vaccines, and uses thereof
BR0316224A (pt) Sequência de dna da região genÈmica tcd de photorhabdus luminescens
BR0308659A (pt) Proteìnas inseticidas do bacillus thuringiensis
BR0010222A (pt) Vetores de expressão viral
ATE443525T1 (de) Antigen-zufuhrsystem

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties